HQY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HQY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-26), HealthEquity's current share price is $79.27. HealthEquity's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $7.24. HealthEquity's Cyclically Adjusted PS Ratio for today is 10.95.
The historical rank and industry rank for HealthEquity's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, HealthEquity's highest Cyclically Adjusted PS Ratio was 12.87. The lowest was 8.54. And the median was 10.28.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
HealthEquity's adjusted revenue per share data for the three months ended in Jan. 2024 was $2.992. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.24 for the trailing ten years ended in Jan. 2024.
The historical data trend for HealthEquity's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 10.01 | 8.34 | 10.15 | 10.28 | 10.44 |
For the Health Information Services subindustry, HealthEquity's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where HealthEquity's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
HealthEquity's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 79.27 | / | 7.24 | |
= | 10.95 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 is calculated as:
For example, HealthEquity's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Jan. 2024 (Change) | * | Current CPI (Jan. 2024) |
= | 2.992 | / | 130.1244 | * | 130.1244 | |
= | 2.992 |
Current CPI (Jan. 2024) = 130.1244.
HealthEquity Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201404 | 0.408 | 100.023 | 0.531 |
201407 | 0.501 | 100.520 | 0.649 |
201410 | 0.380 | 100.176 | 0.494 |
201501 | 0.434 | 98.604 | 0.573 |
201504 | 0.517 | 99.824 | 0.674 |
201507 | 0.517 | 100.691 | 0.668 |
201510 | 0.516 | 100.346 | 0.669 |
201601 | 0.604 | 99.957 | 0.786 |
201604 | 0.741 | 100.947 | 0.955 |
201607 | 0.741 | 101.524 | 0.950 |
201610 | 0.722 | 101.988 | 0.921 |
201701 | 0.774 | 102.456 | 0.983 |
201704 | 0.903 | 103.167 | 1.139 |
201707 | 0.921 | 103.278 | 1.160 |
201710 | 0.918 | 104.070 | 1.148 |
201801 | 0.970 | 104.578 | 1.207 |
201804 | 1.115 | 105.708 | 1.373 |
201807 | 1.121 | 106.324 | 1.372 |
201810 | 1.103 | 106.695 | 1.345 |
201901 | 1.211 | 106.200 | 1.484 |
201904 | 1.362 | 107.818 | 1.644 |
201907 | 1.321 | 108.250 | 1.588 |
201910 | 2.228 | 108.577 | 2.670 |
202001 | 2.780 | 108.841 | 3.324 |
202004 | 2.628 | 108.173 | 3.161 |
202007 | 2.433 | 109.318 | 2.896 |
202010 | 2.304 | 109.861 | 2.729 |
202101 | 2.390 | 110.364 | 2.818 |
202104 | 2.253 | 112.673 | 2.602 |
202107 | 2.265 | 115.183 | 2.559 |
202110 | 2.154 | 116.696 | 2.402 |
202201 | 2.428 | 118.619 | 2.663 |
202204 | 2.448 | 121.978 | 2.611 |
202207 | 2.441 | 125.002 | 2.541 |
202210 | 2.555 | 125.734 | 2.644 |
202301 | 2.760 | 126.223 | 2.845 |
202304 | 2.839 | 127.992 | 2.886 |
202307 | 2.821 | 128.974 | 2.846 |
202310 | 2.861 | 129.810 | 2.868 |
202401 | 2.992 | 130.124 | 2.992 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of HealthEquity's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Delano Ladd | officer: Executive VP, GC & Corp. Secy. | 15W. SCENIC POINTE DR., SUITE 100, DRAPER UT 84020 |
Ian Sacks | director | TOWERBROOK CAP., PARK AVENUE TOWER, 65 E 55TH ST., 27TH FLOOR, NEW YORK NY 10022 |
Elimelech Rosner | officer: EVP, Chief Technology Officer | 5196 BELMORE COURT, SUWANEE GA 30024 |
Stephen Neeleman | director, officer: Founder and Vice Chairman | 15 W. SCENIC POINTE DR., STE. 100, DRAPER UT 84020 |
Tyson D. Murdock | officer: EVP & CFO | 2275 S. 2200 E., SALT LAKE CITY UT 84109 |
Jon Kessler | director, officer: President and CEO | 15 W. SCENIC POINTE DR., STE. 100, DRAPER UT 84020 |
Frank Corvino | director | GREENWICH HOSPITAL, 5 PERRYRIDGE ROAD, GREENWICH CT 06830 |
Larry L Trittschuh | officer: EVP Chief Security Officer | 1051 RUNNYMEDE ROAD, OAKWOOD OH 45419 |
James M Lucania | officer: EVP & CFO | 101 WOLF DRIVE, THOROFARE NJ 08086 |
Gayle Furgurson Wellborn | director | 123 TORRENCE CHAPEL ROAD, MOORESVILLE NC 28117 |
Debra Charlotte Mccowan | director | 1436 CABRILLO AVENUE, BURLINGAME CA 94010 |
Paul Black | director | 400 WOOD ROAD, BRAINTREE MA 02184 |
Edward Bloomberg | officer: Chief Operating Officer | 13207 WINDSOR STREET, LEAWOOD KS 66209 |
Rajesh Natarajan | director | 7500 DALLAS PARKWAY, SUITE 700, PLANO TX 75024 |
Evelyn S Dilsaver | director | C/O LONGS DRUG STORES CORPORATION, 141 NORTH CIVIC DRIVE, WALNUT CREEK CA 94596 |
From GuruFocus
By GuruFocus Research • 12-15-2023
By sperokesalga sperokesalga • 02-14-2023
By GuruFocus Research • 12-22-2023
By sperokesalga sperokesalga • 06-14-2023
By Marketwired • 07-18-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 12-13-2022
By Value_Insider Value_Insider • 11-01-2022
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 09-19-2023